CAS: 1949802-49-6

PI3K/mTOR Inhibitor-1 is a potent, orally bioavailable dual inhibitor of PI3K/mTOR (PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ/mTOR with IC50s of 20/376/204/46/186 nM)

PI3K/mTOR inhibitor-1 is a potent dual inhibitor targeting the phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) pathways. These pathways are critical regulators in controlling cell growth, proliferation, and survival, originating from complex intracellular signaling cascades. PI3K/mTOR inhibitor-1 exerts its mechanism of action by competitively binding to the ATP-binding site of both PI3K and mTOR kinases, effectively hindering their catalytic activities. This blockade disrupts downstream signaling, leading to the inhibition of tumor cell proliferation and induction of apoptosis. In the realm of oncology research, PI3K/mTOR inhibitor-1 is leveraged for its capacity to obstruct aberrant signaling pathways commonly activated in various cancers, including breast, prostate, and glioblastoma. Its application extends to preclinical studies aimed at uncovering therapeutic potential and mechanisms of resistance, providing a valuable tool for dissecting the complexities of PI3K/mTOR-related oncogenesis. Scientists utilize this inhibitor to explore synergistic effects when combined with other cancer therapeutics, with the goal of enhancing efficacy and overcoming resistance in cancer treatment regimens.